BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AMX-883 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of AMX-883\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07723703-2928@assetmemo.bio
DTSTAMP:20261121T005441Z
DTSTART;VALUE=DATE:20281204
DTEND;VALUE=DATE:20281205
SUMMARY:AMX-883: Phase 1 readout est. (NCT07723703)
DESCRIPTION:AMX-883\, phase 1\, Acute Myeloid Leukemia.\nStudy: Phase 1 Ope
 n-label Study of AMX-883 Alone in Participants With AML and High-risk MDS 
 and in Combination in Participants With AML\nEstimated primary completion:
  4 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/amx
 -883#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07723703
URL:https://assetmemo.bio/drug/amx-883#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
